Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Share-based Compensation (2023 - 2025)

Compass Therapeutics' Share-based Compensation history spans 3 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 18.45% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $8.4 million, down 2.24%, while the annual FY2025 figure was $8.4 million, 2.24% down from the prior year.
  • Share-based Compensation for Q4 2025 was $1.8 million at Compass Therapeutics, up from $1.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.8 million in Q2 2025 and bottomed at $1.2 million in Q3 2025.
  • The 3-year median for Share-based Compensation is $1.9 million (2024), against an average of $1.9 million.
  • The largest annual shift saw Share-based Compensation surged 58.09% in 2024 before it plummeted 43.68% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $1.6 million in 2023, then skyrocketed by 39.88% to $2.2 million in 2024, then fell by 18.45% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Share-based Compensation are $1.8 million (Q4 2025), $1.2 million (Q3 2025), and $2.8 million (Q2 2025).